My Treatment Approach: Expert Insights Into the Management of Polycythemia Vera : Episode 13

Opinion

Video

September 22, 2023

Future Perspectives in the Treatment of Polycythemia Vera

Author(s):

John Mascarenhas, MD,Joe Scandura, MD, PhD

John Mascarenhas, MD, and Joe Scandura, MD, PhD, close their discussion by highlighting what to look forward to in the future of polycythemia vera treatment.

EP: 1.Risk Assessment in Patients With Polycythemia Vera (PV)

EP: 2.Reducing Risk of Disease Progression in Patients With PV

EP: 3.Typical Presentation of a Patient With PV

EP: 4.Importance of Bone Marrow Biopsy For Diagnosis of PV

EP: 5.Reducing Risk of Thrombosis in Patients With PV

EP: 6.Factoring Symptom Burden Into Treatment Decision-Making for Patients With PV

EP: 7.Managing Toxicities of Hydroxyurea in Patients With PV

EP: 8.Managing Toxicities of Ropeginterferon Alpha-2b in Patients With PV

EP: 9.Key Trials in the Treatment of PV

EP: 10.Treatment Approaches for High-Risk Patients With PV

EP: 11.Influence of Driver Mutations on Response to Ropeginterferon Alpha-2b in Patients with PV

EP: 12.Ruxolitinib in the Treatment of PV

Now Viewing

EP: 13.Future Perspectives in the Treatment of Polycythemia Vera

Related Content

November 15th 2024

Venetoclax Plus 10-Day Decitabine Produces Responses in High-Risk MDS, AML

March 18th 2024

Revisit the OncLive On Air Episodes From February 2024

November 13th 2024

Tamibarotene Plus Azacitidine Fails to Improve CR Rates in High-Risk, RARA+ MDS

November 20th 2023

FDA Approval Insights: Ivosidenib in R/R IDH1+ Myelodysplastic Syndrome

Ruxolitinib plus low-dose pegylated interferon alfa-2a is well tolerated and efficacious in patients with newly diagnosed polycythemia vera.

November 5th 2024

Ruxolitinib Plus Pegylated Interferon Alfa-2a Is Safe and Effective in Newly-Diagnosed PV

Daniel DeAngelo MD, PhD, of Dana-Farber Cancer Institute

October 28th 2024

JAK Inhibitors Remain the Gold Standard in Myelofibrosis